Advertisement
STAA vs XRAY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STAA is a Hold and XRAY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
STAA’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).
- STAA’s FA Score: 0 green, 5 red.
- XRAY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
STAA’s TA Score shows that 5 TA indicator(s) are bullish while XRAY’s TA Score has 4 bullish TA indicator(s).
- STAA’s TA Score: 5 bullish, 4 bearish.
- XRAY’s TA Score: 4 bullish, 4 bearish.
Price Growth
STAA (@Pharmaceuticals: Other) experienced а +2.32% price change this week, while XRAY (@Pharmaceuticals: Other) price change was -6.87% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.62%. For the same industry, the average monthly price growth was +0.59%, and the average quarterly price growth was +8.86%.
Reported Earning Dates
STAA is expected to report earnings on Feb 25, 2026.
XRAY is expected to report earnings on Feb 26, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.62% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| STAA | XRAY | STAA / XRAY | |
| Capitalization | 1.31B | 2.01B | 65% |
| EBITDA | -73.24M | -689M | 11% |
| Gain YTD | 8.893 | -45.009 | -20% |
| P/E Ratio | 49.73 | N/A | - |
| Revenue | 224M | 3.67B | 6% |
| Total Cash | 190M | 1.27B | 15% |
| Total Debt | 40.5M | 2.49B | 2% |
STAA | XRAY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 95 | |
PRICE GROWTH RATING 1..100 | 50 | 65 | |
P/E GROWTH RATING 1..100 | 85 | 83 | |
SEASONALITY SCORE 1..100 | 90 | 36 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (3) in the Medical Specialties industry is significantly better than the same rating for STAA (86). This means that XRAY’s stock grew significantly faster than STAA’s over the last 12 months.
XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STAA (100). This means that XRAY’s stock grew similarly to STAA’s over the last 12 months.
STAA's SMR Rating (93) in the Medical Specialties industry is in the same range as XRAY (95). This means that STAA’s stock grew similarly to XRAY’s over the last 12 months.
STAA's Price Growth Rating (50) in the Medical Specialties industry is in the same range as XRAY (65). This means that STAA’s stock grew similarly to XRAY’s over the last 12 months.
XRAY's P/E Growth Rating (83) in the Medical Specialties industry is in the same range as STAA (85). This means that XRAY’s stock grew similarly to STAA’s over the last 12 months.
| STAA | XRAY | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 71% | 1 day ago 60% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 52% |
| Momentum ODDS (%) | 1 day ago 75% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 72% | 1 day ago 74% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 75% |
| Advances ODDS (%) | 4 days ago 73% | 29 days ago 56% |
| Declines ODDS (%) | 9 days ago 85% | 1 day ago 74% |
| BollingerBands ODDS (%) | 7 days ago 74% | 1 day ago 51% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 72% |
Advertisement
XRAY and
Correlation & Price change
A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with AZTA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then AZTA could also see price increases.
| Ticker / NAME | Correlation To XRAY | 1D Price Change % | ||
|---|---|---|---|---|
| XRAY | 100% | -1.61% | ||
| AZTA - XRAY | 58% Loosely correlated | +2.07% | ||
| NVST - XRAY | 55% Loosely correlated | -0.94% | ||
| ALGN - XRAY | 53% Loosely correlated | +1.10% | ||
| QDEL - XRAY | 50% Loosely correlated | -1.32% | ||
| KIDS - XRAY | 48% Loosely correlated | +1.65% | ||
More | ||||